Curia Bio Inc.
Albany, NY Part of Curia Global Inc.
- UEI
- PW5LPREDN9N5
- CAGE
- 9TMX2
- Primary NAICS
- 541380 Testing Laboratories and Services
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Curia Global Inc. · Albany, NY
ELCNZCS8GEA3
-
Parent
Curia Global Inc. · Albany, NY
ELCNZCS8GEA3
- SAM.gov registration date
- Physical address
- 24 Corporate Cir, Albany, NY 12203, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $61,550 |
| FY2024 | $32,100 |
Contract awards
Similar vendors
About the company
Curia Bio Inc. is a corporate entity registered in SAM.gov, located in Albany, New York, that provides specialized scientific research and development services to federal agencies. The company appears to focus on advanced biotechnology and preclinical research, particularly in areas involving viral research, antibody development, and cancer prevention. Its primary service offerings include molecular evaluation, sample purification, virus-related research, and preclinical drug development across multiple scientific domains.
Through its federal contract awards, Curia Bio Inc. has demonstrated capabilities in complex scientific research services for multiple federal agencies. The company has executed purchase order contracts with the Department of Veterans Affairs for material generation and molecular evaluation of human monoclonal antibodies, and with the National Institute of Allergy and Infectious Diseases for sample purification services relating to dengue (DENV) and Zika (ZIKV) viruses. These contracts, valued between $32,100 and $61,550, involve sophisticated scientific processes such as in silico developability assessment, biophysical profiling, sequence evaluation, structure modeling, immunogenicity assessment, protein purification, and analytical characterization. None of these contracts utilized set-aside designations, indicating open competition.
Curia Bio Inc. has secured a significant Indefinite Delivery Contract (IDC) with the National Cancer Institute valued at $149,995,000, with a performance period through January 24, 2029. This single-award IDC supports the PREVENT Cancer Preclinical Drug Development Program and includes three distinct IDIQ pools: (1) evaluating efficacy and biomarkers for chemopreventive and immunopreventive regimens, (2) preclinical product development and CGMP manufacturing for cancer preventive vaccines, and (3) pharmacological and toxicological testing of potential cancer preventative agents. The contract will be performed at Curia Bio's facilities and does not utilize any set-aside designations, representing a comprehensive approach to supporting cancer prevention research and development across multiple scientific disciplines.
Quick answers
Is Curia Bio Inc. registered in SAM.gov?
Yes. Curia Bio Inc.'s SAM.gov registration is active through May 18, 2027.
How much has Curia Bio Inc. received in federal contracts?
Federal contracts obligated $61,550 to Curia Bio Inc. in fiscal year 2025 and $93,650 in fiscal years 2023 through 2027.
What is Curia Bio Inc.'s most recent federal award?
Curia Bio Inc.'s most recent federal contract award is Material generation and molecular evaluation contract (36C26025P1064), from Veterans Integrated Service Network 20 (VHA), on September 1, 2025.
On GovTribe
See Curia Bio Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors